







































Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):50-55 

[50]                                                                                                                                                                                                                                              AJDHS.COM 

 

 

Available online at ajdhs.com 

Asian Journal of Dental and Health Sciences 
Open Access to Dental and Medical Research 

Copyright  © 2024 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided 

the original author and source are credited 
 

 

 

Gut Mucosal Immunity in HIV-Exposed Infants: A Review 
*Emmanuel Ifeanyi Obeagu 1  and Getrude Uzoma Obeagu 2 

1 Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda. 

2 School of Nursing Science, Kampala International University, Ishaka, Uganda. 

Article Info: 
_____________________________________________ 
Article History: 

Received   17 April 2024     
Reviewed  28 May 2024 
Accepted   24 June 2024 
Published 15 July 2024 

_____________________________________________ 
Cite this article as:  

Obeagu EI, Obeagu GU, Gut Mucosal 
Immunity in HIV-Exposed Infants: A Review, 
Asian Journal of Dental and Health Sciences. 2024; 
4(2):50-55 

DOI: http://dx.doi.org/10.22270/ajdhs.v4i2.82     

_____________________________________________ 

*Address for Correspondence:   

Emmanuel Ifeanyi Obeagu, Department of Medical 
Laboratory Science, Kampala International 
University, Uganda 

Abstract 
_________________________________________________________________________________________________________________ 

Gut mucosal immunity in infants exposed to Human Immunodeficiency Virus (HIV) presents a 
complex interplay of developmental processes, viral dynamics, and therapeutic interventions that 
significantly impact clinical outcomes. This review synthesizes current knowledge on the 
mechanisms, clinical implications, and therapeutic strategies concerning gut mucosal immunity in 
HIV-exposed infants. The gut mucosa serves as a critical site for immune maturation and defense 
against pathogens, but HIV infection disrupts this delicate balance, leading to compromised immune 
function and increased susceptibility to infections.  Infants born to HIV-positive mothers experience 
unique challenges in gut mucosal immunity due to vertical transmission of the virus and exposure 
to antiretroviral therapy (ART). HIV infection disrupts gut-associated lymphoid tissue (GALT), 
resulting in early depletion of CD4+ T cells and compromised mucosal barrier function. These 
alterations contribute to microbial translocation, chronic inflammation, and immune dysregulation, 
impacting overall immune competence and increasing susceptibility to opportunistic infections. 
Despite advances in ART, persistent immune activation and residual gut mucosal damage pose 
ongoing challenges in achieving optimal immune reconstitution and preventing long-term 
complications in HIV-exposed infants. Clinical implications of compromised gut mucosal immunity 
in HIV-exposed infants extend beyond gastrointestinal health to encompass systemic immune 
dysfunction and increased risks of non-AIDS comorbidities. Impaired gut barrier function 
exacerbates microbial translocation, leading to systemic inflammation that may contribute to 
neurodevelopmental abnormalities and metabolic disorders. 

Keywords: Gut, Immunity, HIV, Infants  

 

Introduction 

Human Immunodeficiency Virus (HIV) infection continues to 
pose significant global health challenges, particularly affecting 
vulnerable populations such as infants born to HIV-positive 
mothers. Vertical transmission of HIV remains a leading cause 
of pediatric HIV infections, highlighting the critical need for 
effective prevention, early diagnosis, and optimal management 
strategies. Infants exposed to HIV face unique immunological 
challenges, particularly in the development and maintenance of 
gut mucosal immunity, which plays a crucial role in immune 
maturation, defense against pathogens, and overall health 
outcomes.1-2 The gut mucosa serves as a dynamic interface 
where complex interactions occur between the host immune 
system, commensal microbiota, and potential pathogens. In 
neonates and infants, the gut mucosa undergoes rapid 
development and maturation, crucial for establishing immune 
tolerance, regulating inflammatory responses, and shaping 
systemic immune function. However, in the context of HIV 
exposure, this delicate balance is disrupted early in life, 
impacting both local mucosal immunity and systemic immune 
responses. Understanding the mechanisms underlying gut 
mucosal immune dysfunction in HIV-exposed infants is 
therefore pivotal for developing targeted interventions to 
mitigate immune perturbations and improve clinical 
outcomes.3-4 HIV infection profoundly affects gut-associated 
lymphoid tissue (GALT), comprising organized lymphoid 
structures such as Peyer's patches and gut-associated lymph 
nodes, as well as diffuse lymphoid aggregates in the lamina 

propria. These mucosal sites are critical for generating and 
maintaining adaptive immune responses against enteric 
pathogens. However, HIV selectively targets CD4+ T cells, 
particularly gut-homing CCR5+ CD4+ T cells, leading to their 
depletion and disruption of GALT architecture. Loss of CD4+ T 
cells compromise mucosal barrier integrity, impairs local 
immune surveillance, and promotes microbial translocation 
across the intestinal epithelium, contributing to chronic 
immune activation and systemic inflammation.5-6 

The consequences of disrupted gut mucosal immunity in HIV-
exposed infants extend beyond gastrointestinal health to 
impact overall immune competence and susceptibility to 
infections. Impaired gut barrier function allows for increased 
translocation of microbial products, such as 
lipopolysaccharides (LPS) and bacterial DNA fragments, into 
systemic circulation, triggering innate immune responses and 
perpetuating chronic inflammation. Persistent immune 
activation is associated with accelerated immune senescence, 
characterized by premature immune aging, reduced immune 
reconstitution, and heightened susceptibility to opportunistic 
infections and non-AIDS comorbidities.7-8 Antiretroviral 
therapy (ART) represents a cornerstone of treatment in 
pediatric HIV infection, effectively suppressing viral replication 
and preserving immune function. Early initiation of ART in HIV-
exposed infants is crucial for preventing disease progression 
and reducing the establishment of viral reservoirs. However, 
despite viral suppression, ART alone may not fully restore gut 
mucosal immunity or mitigate chronic inflammation in HIV-

                     Open Access                                                                                                                                                                                                          Review Article                                                                           

http://jddtonline.info/
http://dx.doi.org/10.22270/ajdhs.v4i2.82
https://crossmark.crossref.org/dialog/?doi=10.22270/ajdhs.v4i2.82&amp;domain=pdf
https://orcid.org/0000-0002-4538-0161


Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):50-55 

[51]                                                                                                                                                                                                                                              AJDHS.COM 

infected children. Persistent immune activation and residual 
gut mucosal damage underscore the need for adjunctive 
therapies aimed at modulating immune responses and 
enhancing mucosal integrity.9-10 

Gut Mucosal Immunity in HIV-Exposed Infants 

The gut mucosa plays a pivotal role in immune development, 
acting as a barrier against pathogens while maintaining 
tolerance to commensal microbiota. However, HIV infection 
disrupts this delicate balance, leading to significant alterations 
in gut-associated lymphoid tissue (GALT), mucosal immune 
responses, and microbial composition.11 HIV targets CD4+ T 
cells, particularly gut-homing CCR5+ CD4+ T cells, which are 
crucial for maintaining GALT integrity and regulating mucosal 
immunity. The depletion of these cells compromises mucosal 
barrier function, increases gut permeability, and facilitates the 
translocation of microbial products into systemic circulation. 
This process, known as microbial translocation, triggers 
chronic immune activation and inflammation, which are 
hallmarks of HIV pathogenesis and contribute to disease 
progression in infants.12-13 Studies have shown that HIV-
exposed infants exhibit early and persistent abnormalities in 
gut mucosal immunity, even in the absence of clinical 
symptoms. These abnormalities include reduced levels of GALT 
CD4+ T cells, altered cytokine profiles, and dysbiosis of the gut 
microbiota. Dysregulated immune responses in the gut mucosa 
not only impair local defenses against enteric pathogens but 
also impact systemic immune function, potentially influencing 
the course of HIV infection and complicating treatment 
outcomes.14-15 The consequences of impaired gut mucosal 
immunity in HIV-exposed infants extend beyond 
gastrointestinal health to affect overall immune competence 
and susceptibility to infections. Chronic immune activation 
associated with gut mucosal damage may contribute to immune 
exhaustion, premature immune senescence, and impaired 
responses to vaccination. Addressing these challenges requires 
a multifaceted approach, including early initiation of 
antiretroviral therapy (ART), nutritional interventions to 
support gut health, and research into novel strategies to restore 
mucosal immune function and mitigate immune 
dysregulation.16-17 

Clinical Implications 

The clinical implications of altered gut mucosal immunity in 
HIV-exposed infants are profound and multifaceted, influencing 
both immediate management strategies and long-term health 
outcomes. Here, we explore these implications in detail: 

1. Increased Susceptibility to Infections: Impaired gut 
mucosal integrity and dysregulated immune responses in 
HIV-exposed infants contribute to heightened susceptibility 
to enteric infections and systemic infections. The depletion 
of CD4+ T cells in gut-associated lymphoid tissue (GALT) 
compromises local immune defenses against pathogens, 
leading to frequent gastrointestinal infections such as 
diarrhea and opportunistic infections. These infections not 
only impact nutritional status and growth but also pose 
challenges in clinical management due to recurrent illness 
and the need for aggressive antimicrobial therapies.18-20 

2. Impact on Nutritional Status and Growth: The gut 
mucosa plays a critical role in nutrient absorption and 
metabolism. HIV-associated gut mucosal damage can 
impair nutrient uptake, leading to malabsorption 
syndromes and nutritional deficiencies in infants. 
Persistent diarrhea and enteropathy further exacerbate 
nutritional challenges, affecting growth and development 
during a critical period of infancy. Optimizing nutritional 
support, including micronutrient supplementation and 

specialized formulas, is essential to mitigate these effects 
and support optimal growth in HIV-exposed infants.21-23 

3. Immune Dysregulation and Chronic Inflammation: HIV-
induced immune dysregulation in the gut mucosa 
contributes to chronic inflammation characterized by 
elevated levels of pro-inflammatory cytokines and 
microbial translocation. Chronic immune activation not 
only accelerates disease progression but also increases the 
risk of non-AIDS comorbidities, including cardiovascular 
disease, neurodevelopmental impairments, and metabolic 
disorders. Managing chronic inflammation in HIV-exposed 
infants requires a comprehensive approach that includes 
early initiation of antiretroviral therapy (ART), monitoring 
of inflammatory markers, and potentially anti-
inflammatory interventions to mitigate long-term immune 
dysfunction.24-26 

4. Impact on Neurodevelopment and Cognitive Function: 
Emerging evidence suggests a link between gut health, 
immune function, and neurodevelopment in HIV-exposed 
infants. Chronic inflammation and microbial dysbiosis in 
the gut may contribute to neuroinflammation and 
neurocognitive impairments, influencing cognitive 
development and behavioral outcomes. Addressing gut 
mucosal immunity as part of comprehensive pediatric HIV 
care is therefore crucial for optimizing neurodevelopmental 
outcomes and quality of life for affected infants.27-28 

5. Implications for Vaccine Responses: Effective 
vaccination is essential for preventing opportunistic 
infections in HIV-exposed infants. However, impaired gut 
mucosal immunity and immune dysregulation may 
compromise vaccine responses, leading to reduced efficacy 
of routine childhood vaccines and vaccines against 
opportunistic infections such as pneumococcus and 
rotavirus. Strategies to enhance vaccine responses, 
including booster doses and novel adjuvanted vaccines, are 
needed to overcome these challenges and improve 
protective immunity in this vulnerable population.29-31 

6. Long-Term Health Monitoring and Management: 
Longitudinal monitoring of gut mucosal integrity, immune 
function, and growth parameters is essential for optimizing 
clinical outcomes in HIV-exposed infants. Comprehensive 
health assessments, including screening for gastrointestinal 
complications, growth monitoring, and 
neurodevelopmental assessments, facilitate early detection 
and management of complications associated with 
impaired gut mucosal immunity. Multidisciplinary care 
teams, comprising pediatricians, infectious disease 
specialists, nutritionists, and developmental psychologists, 
collaborate to provide integrated care that addresses the 
complex health needs of HIV-exposed infants and supports 
long-term health and well-being.32-35 

Challenges 

Addressing the challenges associated with gut mucosal 
immunity in HIV-exposed infants is crucial for optimizing 
clinical management and improving long-term health 
outcomes. These challenges span various aspects of care and 
research: 

1. Early Diagnosis and Access to Care: One of the primary 
challenges is ensuring early diagnosis of HIV infection in 
infants born to HIV-positive mothers. Access to early infant 
diagnosis (EID) services remains limited in many resource-
limited settings, delaying the initiation of antiretroviral 
therapy (ART) and potentially compromising immune 
reconstitution. Timely identification of HIV-exposed infants 
is essential to mitigate the impact of viral exposure on gut 
mucosal immunity and overall health outcomes.36-37 



Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):50-55 

[52]                                                                                                                                                                                                                                              AJDHS.COM 

2. Impact of Vertical Transmission and Breastfeeding: 
Vertical transmission of HIV remains a significant mode of 
infection in infants. Breastfeeding poses additional 
challenges, as it provides nutritional benefits while also 
potentially exposing infants to the virus. Balancing the 
nutritional advantages of breastfeeding with the risk of HIV 
transmission requires careful counseling and support for 
mothers, as well as adherence to ART regimens to reduce 
viral load and minimize transmission risk.38-39 

3. Gut Mucosal Damage and Immune Dysfunction: HIV 
infection disrupts gut-associated lymphoid tissue (GALT), 
leading to early depletion of CD4+ T cells and compromised 
mucosal barrier function. This damage contributes to 
microbial translocation, chronic immune activation, and 
systemic inflammation, which in turn increase the risk of 
opportunistic infections and non-AIDS comorbidities. 
Addressing gut mucosal damage and immune dysfunction 
requires targeted interventions to preserve mucosal 
integrity and enhance immune reconstitution.40-41 

4. Antiretroviral Therapy (ART) Challenges: While ART is 
effective in suppressing viral replication and preserving 
immune function, challenges such as adherence, drug 
resistance, and side effects impact treatment outcomes in 
HIV-exposed infants. Pediatric formulations of ART may be 
limited, leading to dosing challenges and suboptimal 
adherence. Optimizing ART regimens and developing 
pediatric-friendly formulations are critical to ensure 
sustained viral suppression and mitigate the long-term 
effects of HIV on gut mucosal immunity.42-43 

5. Nutritional and Developmental Implications: Impaired 
gut mucosal immunity in HIV-exposed infants can lead to 
malabsorption syndromes, nutritional deficiencies, and 
growth faltering. Nutritional interventions are essential to 
support gut health and promote optimal growth and 
development. However, access to adequate nutrition, 
especially in resource-limited settings, remains a challenge 
and can exacerbate the impact of HIV on immune and 
overall health outcomes.44-45 

6. Research and Resource Limitations: Research into gut 
mucosal immunity in pediatric HIV infection faces 
challenges related to funding, infrastructure, and access to 
specialized laboratories and expertise. Longitudinal studies 
are needed to understand the long-term effects of HIV on 
gut health, immune function, and neurodevelopment in 
infants. Collaborative efforts among researchers, healthcare 
providers, policymakers, and community stakeholders are 
essential to address these challenges and advance 
knowledge in pediatric HIV care.46-47 

7. Social and Psychosocial Factors: Stigma associated with 
HIV/AIDS can hinder access to healthcare services and 
adherence to treatment regimens, impacting overall health 
outcomes in HIV-exposed infants. Addressing social 
determinants of health, promoting maternal and family 
support, and integrating psychosocial support services into 
pediatric HIV care are crucial to improving treatment 
adherence, reducing stigma, and supporting holistic care for 
affected infants and their families.48-49 

Therapeutic Strategies 

Therapeutic strategies for addressing gut mucosal immunity in 
HIV-exposed infants aim to mitigate immune dysfunction, 
preserve mucosal integrity, and improve long-term health 
outcomes. These strategies involve a combination of medical 
interventions, nutritional support, and supportive care 
approaches tailored to the unique needs of pediatric patients. 
Here are key therapeutic strategies: 

1. Early Initiation of Antiretroviral Therapy (ART): Early 
initiation of ART is critical to suppress viral replication, 
preserve CD4+ T cell counts, and prevent further damage to 
gut mucosal immunity. ART reduces viral load, which in 
turn decreases viral-induced immune activation and 
inflammation in the gut mucosa. Pediatric ART regimens, 
including fixed-dose combinations and age-appropriate 
formulations, ensure optimal dosing and adherence in 
infants.50 

2. Nutritional Support: Optimal nutrition is essential for 
supporting gut mucosal health and immune function in HIV-
exposed infants. Malnutrition and nutrient deficiencies can 
exacerbate immune dysfunction and impair growth. 
Nutritional interventions include breastfeeding promotion 
with adherence to ART by the mother, provision of infant 
formula when necessary, and supplementation with 
essential micronutrients such as vitamins and minerals. 
Nutrition counseling for caregivers ensures adequate 
dietary intake and growth monitoring.51 

3. Management of Opportunistic Infections: Preventing 
and treating opportunistic infections are crucial 
components of pediatric HIV care. Infants with 
compromised gut mucosal immunity are at increased risk 
of gastrointestinal infections and systemic infections. 
Prophylactic antibiotics, antifungals, and vaccines (e.g., 
pneumococcal and rotavirus vaccines) help prevent 
infections. Early recognition and prompt treatment of 
infections reduce morbidity and mortality, supporting 
overall immune health.52 

4. Promotion of Breastfeeding with ART: Breastfeeding 
provides essential nutrients and immune factors that 
support infant health. The benefits of breastfeeding must be 
balanced against the risk of HIV transmission. Exclusive 
breastfeeding with maternal ART adherence significantly 
reduces the risk of vertical transmission. Counseling 
mothers on safe breastfeeding practices and ensuring viral 
suppression through ART are critical to minimize 
transmission risk while promoting infant health.53 

5. Immune Modulation Therapies: Innovative therapies 
aimed at modulating immune responses in HIV-exposed 
infants are under investigation. These include interventions 
to reduce chronic immune activation and inflammation, 
such as anti-inflammatory agents or immune checkpoint 
inhibitors. Research into probiotics and prebiotics to 
restore gut microbial balance (microbiota) and enhance 
mucosal immunity is also promising for improving gut 
health and immune function.54 

6. Monitoring and Management of Gut Health: Regular 
monitoring of gut mucosal integrity and immune function is 
essential for early detection of complications and timely 
intervention. Biomarkers of gut mucosal damage, such as 
fecal calprotectin and zonulin levels, can aid in assessing 
mucosal health. Endoscopic evaluations and 
histopathological assessments provide insights into 
mucosal inflammation and damage, guiding therapeutic 
decisions.55-56 

7. Psychosocial Support: Addressing psychosocial factors, 
including stigma associated with HIV/AIDS, is crucial for 
promoting adherence to treatment and overall well-being 
in affected infants and their families. Supportive care 
services, including counseling, peer support groups, and 
community outreach programs, help reduce stigma, 
improve treatment adherence, and enhance quality of life 
for HIV-exposed infants and their caregivers.57-58 

8. Research and Development: Continued research into 
novel therapeutic approaches, including vaccines targeting 



Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):50-55 

[53]                                                                                                                                                                                                                                              AJDHS.COM 

mucosal immunity and immune modulation therapies, is 
essential to advance pediatric HIV care. Collaborative 
efforts among researchers, healthcare providers, and 
pharmaceutical companies are needed to develop new 
treatment options tailored to the unique immunological 
challenges of HIV-exposed infants.59 

Conclusion 

Gut mucosal immunity in HIV-exposed infants represents a 
critical area of research and clinical management, with 
profound implications for immune development, infectious 
disease susceptibility, and long-term health outcomes. HIV 
infection disrupts the delicate balance of gut-associated 
lymphoid tissue (GALT), leading to early depletion of CD4+ T 
cells, compromised mucosal barrier function, and chronic 
immune activation. These immunological perturbations 
contribute to increased susceptibility to infections, nutritional 
challenges, and systemic inflammation, impacting overall 
health and quality of life in affected infants. Addressing the 
challenges associated with gut mucosal immunity in HIV-
exposed infants requires a multifaceted approach that 
integrates early diagnosis, optimized antiretroviral therapy 
(ART), nutritional support, management of opportunistic 
infections, and innovative immune modulation strategies. Early 
initiation of ART is pivotal in suppressing viral replication, 
preserving immune function, and mitigating mucosal damage. 
Nutritional interventions, including breastfeeding with ART 
adherence and nutrient supplementation, support optimal 
growth and immune health, while management of 
opportunistic infections reduces morbidity and mortality. 

References 

1. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, 
Baban B. Innate immunity of neonates and infants. Frontiers in 
immunology. 2018; 9:1759. 
https://doi.org/10.3389/fimmu.2018.01759 PMid:30105028 
PMCid:PMC6077196 

2. Goenka A, Kollmann TR. Development of immunity in early life. 
Journal of Infection. 2015;71: S112-120. 
https://doi.org/10.1016/j.jinf.2015.04.027 PMid:25934325 

3. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and 
role of host defenses in fetal and neonatal susceptibility to 
infection. In Remington and Klein's Infectious Diseases of the 
Fetus and Newborn Infant 2025: 73-159. Elsevier. 
https://doi.org/10.1016/B978-0-323-79525-8.00013-5 

4. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV 
through Blood Transfusions: Clinical Considerations and 
Innovations. Elite Journal of HIV, 2024; 2(1): 16-30 

5. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 
Ratios in HIV. Elite Journal of Scientific Research and Review, 
2024; 2(1): 37-50 

6. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among 
Women Living with HIV: A Comprehensive Review. Int. J. Curr. 
Res. Med. Sci. 2024;10(1):11-24. 

7. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: 
Unveiling Their Role in HIV Progression within Malaria Patients. 
Journal home page: http://www. journalijiar. com.;12(01). 

8. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: 
Implications for Antiviral Therapy. Elite Journal of Scientific 
Research and Review, 2024; 2(1): 17-41 

9. Obeagu EI, Obeagu GU. The Intricate Relationship Between 
Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for 
Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 
2024;11(2):30-40. 

10. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-
Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 
2(1): 51-64 

11. Obeagu EI, Obeagu GU. Strength in Unity: Building Support 
Networks for HIV Patients in Uganda. Elite Journal of Medicine, 
2024; 2(1): 1-16 

12. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues 
of HIV-Positive Pregnant Women: A Review. Elite Journal of 
Laboratory Medicine, 2024; 2(1): 14-32 

13. Kuhn L, Meddows-Taylor S, Gray G, Tiemessen C. Human 
immunodeficiency virus (HIV)-specific cellular immune responses 
in newborns exposed to HIV in utero. Clinical infectious diseases. 
2002;34(2):267-276. https://doi.org/10.1086/338153 
PMid:11740717 

14. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in 
early life. Frontiers in immunology. 2014; 5:391. 
https://doi.org/10.3389/fimmu.2014.00391 PMid:25161656 
PMCid:PMC4130105 

15. Geng ST, Zhang ZY, Wang YX, Lu D, Yu J, Zhang JB, Kuang YQ, Wang 
KH. Regulation of gut microbiota on immune reconstitution in 
patients with acquired immunodeficiency syndrome. Frontiers in 
microbiology. 2020; 11:594820. 
https://doi.org/10.3389/fmicb.2020.594820 PMid:33193273 
PMCid:PMC7652894 

16. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in 
Managing Anemia in HIV: A Review. Elite Journal of Scientific 
Research and Review, 2024; 2(1): 24-36 

17. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies 
for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. 
Res. Chem. Pharm. Sci. 2024;11(2):41-51. 

18. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV 
Patients Receiving Antiretroviral Therapy: Implications for Risk 
Assessment. Elite Journal of HIV, 2024; 2(3): 14-26 

19. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection 
of Highly Active Antiretroviral Therapy and Platelets in HIV 
Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-
117 

20. Obeagu EI, Obeagu GU. Understanding ART and Platelet 
Functionality: Implications for HIV Patients. Elite Journal of HIV, 
2024; 2(2): 60-73 

21. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to 
Mothers with Severe Malaria, HIV, and Transfusion History: A 
Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 
38-58 

22. Obeagu EI. Erythropoietin and the Immune System: Relevance in 
HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-
35 

23. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in 
Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. 
Elite Journal of Immunology, 2024; 2(2): 43-59 

24. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in 
HIV Disease Progression. Elite Journal of Haematology, 2024; 
2(3): 42-57 

25. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: 
Understanding the Interplay between Blood Transfusion and 
Antiretroviral Therapy in HIV Management. Elite Journal of 
Nursing and Health Science, 2024; 2(2): 5-15 

26. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive 
Neonates: Insights and Implications for Clinical Management. Elite 
Journal of Nursing and Health Science, 2024; 2(3): 59-72 

27. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV 
positive patients in FMC owerri. International Journal of Current 
Microbiology and Applied Sciences. 2015;4(4):911-916. 
https://www.academia.edu/download/38320140/Obeagu_Emma
nuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf. 

28. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale 
VL, Baban B. Innate immunity of neonates and infants. Frontiers in 
immunology. 2018; 9:1759. 
https://doi.org/10.3389/fimmu.2018.01759 PMid:30105028 
PMCid:PMC6077196 

https://doi.org/10.3389/fimmu.2018.01759
https://doi.org/10.1016/j.jinf.2015.04.027
https://doi.org/10.1016/B978-0-323-79525-8.00013-5
https://doi.org/10.1086/338153
https://doi.org/10.3389/fimmu.2014.00391
https://doi.org/10.3389/fmicb.2020.594820
https://doi.org/10.3389/fimmu.2018.01759


Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):50-55 

[54]                                                                                                                                                                                                                                              AJDHS.COM 

29. Levy O. Innate immunity of the newborn: basic mechanisms and 
clinical correlates. Nature Reviews Immunology. 2007;7(5):379-
390. https://doi.org/10.1038/nri2075 PMid:17457344 

30. Pieren DK, Boer MC, de Wit J. The adaptive immune system in early 
life: The shift makes it count. Frontiers in immunology. 2022; 
13:1031924. https://doi.org/10.3389/fimmu.2022.1031924 
PMid:36466865 PMCid:PMC9712958 

31. Rackaityte E, Halkias J. Mechanisms of fetal T cell tolerance and 
immune regulation. Frontiers in immunology. 2020; 11:588. 
https://doi.org/10.3389/fimmu.2020.00588 PMid:32328065 
PMCid:PMC7160249 

32. Sereme Y, Toumi E, Saifi E, Faury H, Skurnik D. Maternal immune 
factors involved in the prevention or facilitation of neonatal 
bacterial infections. Cellular Immunology. 2024; 395:104796. 
https://doi.org/10.1016/j.cellimm.2023.104796 PMid:38104514 

33. Zhang X, Zhivaki D, Lo-Man R. Unique aspects of the perinatal 
immune system. Nature Reviews Immunology. 2017;17(8):495-
507. https://doi.org/10.1038/nri.2017.54 PMid:28627520 

34. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. 
Current opinion in microbiology. 2020; 56:30-37. 
https://doi.org/10.1016/j.mib.2020.05.011 PMid:32634598 
PMCid:PMC8729197 

35. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu 
DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive 
measures and management of HIV/AIDS victims among parents in 
Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. 
Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009 
https://doi.org/10.22192/ijarbs.2016.03.10.009 

36. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong 
OE, Odunze U. HIV and TB co-infection among patients who used 
Directly Observed Treatment Short-course centres in Yenagoa, 
Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. 
links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-
among-patients-who-used-Directly-Observed-Treatment-Short-
course-centres-in-Yenagoa-Nigeria.pdf 

37. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile 
Patients with Pulmonary Tuberculosis and Human 
Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna 
University journal of Medicine and Health Sciences. 
2022;2(3):110-119. 

38. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, 
Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. 
Change in Lipid Peroxidation Marker (MDA) and Non enzymatic 
Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban 
Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. 
links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-
PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-
ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-
AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf. 

39. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of 
activated partial thromboplastin time (APTT) among HIV positive 
patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. 
https://www.academia.edu/download/38320159/Obeagu_Emma
nuel_Ifeanyi3__et_al.IJCRAR.pdf. 

40. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. 
Hematological indices o HIV seropositive subjects in Nnamdi 
Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin 
Lab Res. 2018;6(1):1-4. 
links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-
HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf 

41. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, 
Onwuasoanya UF. Impact of prevention of mother to child 
transmission (PMTCT) of HIV on positivity rate in Kafanchan, 
Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 
10.22192/ijcrms.2017.03.02.005 

42. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise 
in HIV cases in Pakistan: Challenges and future recommendations 
at hand. Health Science Reports. 2023;6(8):e1450. 
https://doi.org/10.1002/hsr2.1450 PMid:37520460 
PMCid:PMC10375546 

43. Obeagu EI, Amekpor F, Scott GY. An update of human 
immunodeficiency virus infection: Bleeding disorders. J Pub 
Health Nutri. 2023 

6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-
human-immunodeficiency-virus-infection-Bleeding.pdf. 

44. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula 
C. Prevention of New Cases of Human Immunodeficiency Virus: 
Pragmatic Approaches of Saving Life in Developing Countries. 
Madonna University journal of Medicine and Health Sciences. 
2022;2(3):128-134. 
https://madonnauniversity.edu.ng/journals/index.php/medicine
/article/view/86. 

45. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of 
Activated Partial Thromboplastin Time and Prothrombin Time in 
HIV and TB Patients in Owerri Metropolis. Journal of 
Pharmaceutical Research International. 2022:29-34. 
https://doi.org/10.9734/jpri/2022/v34i3A35560 

46. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, 
Bassey JO, Paul AO. Cascade variabilities in TB case finding among 
people living with HIV and the use of IPT: assessment in three 
levels of care in cross River State, Nigeria. Journal of 
Pharmaceutical Research International. 2020;32(24):9-18. 
https://doi.org/10.9734/jpri/2020/v32i2430789 

47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and 
socio-demographic factors associated with non-adherence to 
antiretroviral therapy among people living with HIV/AIDS. Int. J. 
Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 
10.22192/ijarbs.2023.10.09.015 
links/6516faa61e2386049de5e828/A-Review-of-knowledge-
attitudes-and-socio-demographic-factors-associated-with-non-
adherence-to-antiretroviral-therapy-among-people-living-with-
HIV-AIDS.pdf 

48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review 
of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 
2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 
links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-
Patients-A-review-of-Prevalence-and-Associated-Factors.pdf. 

49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. 
Haematological indices of malaria patients coinfected with HIV in 
Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 
10.22192/ijcrms.2017.03.05.014 
https://www.academia.edu/download/54317126/Haematologic
al_indices_of_malaria_patients_coinfected_with_HIV.pdf  
https://doi.org/10.22192/ijcrms.2017.03.05.014 

50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella 
N. Comparative study of enzyme linked immunosorbent assay 
(Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and 
Syphilis among voluntary donors in. Owerri, Nigeria. J Clin 
Commun Med. 2020;2(3):180-183.DOI: DOI: 
10.32474/JCCM.2020.02.000137 
links/5f344530458515b7291bd95f/Comparative-Study-of-
Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-
Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-
Voluntary-Donors-in-Owerri-Nigeria.pdf. 

51. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors 
Influencing Early Neonatal Adverse Outcomes among Women 
with HIV with Post Dated Pregnancies Delivering at Kampala 
International University Teaching Hospital, Uganda. Asian Journal 
of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. 
http://research.sdpublishers.net/id/eprint/2819/. 

52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. 
Adherence to Antiretroviral Therapy among HIV/AIDS in Federal 
Medical Centre, Owerri. Journal of Pharmaceutical Research 
International. 2021;33(57A):360-368. 
https://doi.org/10.9734/jpri/2021/v33i57A34007 

53. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in 
Human Immunodeficiency Virus, Tuberculosis and Malaria: A 
Review. Madonna University journal of Medicine and Health 
Sciences. 2022;2(3):6-15. 
https://madonnauniversity.edu.ng/journals/index.php/medicine
/article/view/69 

https://doi.org/10.1038/nri2075
https://doi.org/10.3389/fimmu.2022.1031924
https://doi.org/10.3389/fimmu.2020.00588
https://doi.org/10.1016/j.cellimm.2023.104796
https://doi.org/10.1038/nri.2017.54
https://doi.org/10.1016/j.mib.2020.05.011
https://doi.org/10.22192/ijarbs.2016.03.10.009
https://doi.org/10.1002/hsr2.1450
https://doi.org/10.9734/jpri/2022/v34i3A35560
https://doi.org/10.9734/jpri/2020/v32i2430789
https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
https://doi.org/10.22192/ijcrms.2017.03.05.014
https://doi.org/10.9734/jpri/2021/v33i57A34007


Obeagu et al.                                                                                                                                Asian Journal of Dental and Health Sciences. 2024; 4(2):50-55 

[55]                                                                                                                                                                                                                                              AJDHS.COM 

54. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu 
EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV 
INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN 
FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European 
Journal of Pharmaceutical and Medical Research, 2023; 10(8): 
564-568 

55. Wilson EM, Sereti I. Immune restoration after antiretroviral 
therapy: the pitfalls of hasty or incomplete repairs. Immunological 
reviews. 2013;254(1):343-354. 
https://doi.org/10.1111/imr.12064 PMid:23772630 
PMCid:PMC3694599 

56. Misgena DK. The pattern of immunologic and virologic responses 
to Highly Active Antiretroviral Treatment (HAART): Does success 
bring further challenges? Ethiopian Journal of Health 
Development. 2011;25(1):61-70. 
https://doi.org/10.4314/ejhd.v25i1.69853 

57. Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent 
SJ. Functional cure of HIV: the scale of the challenge. Nature 
Reviews Immunology. 2019;19(1):45-54. 
https://doi.org/10.1038/s41577-018-0085-4 PMid:30410126 

58. Geretti AM, Brook G, Cameron C, Chadwick D, French N, 
Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E. 
British HIV Association guidelines on the use of vaccines in HIV-
positive adults 2015. HIV medicine. 2016;17(53):S2-81. 
https://doi.org/10.1111/hiv.12424 PMid:27568789 

59. Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination 
as a preventative measure contributing to immune fitness. npj 
Vaccines. 2021;6(1):93. https://doi.org/10.1038/s41541-021-
00354-z PMid:34315886 PMCid:PMC8316335

 

 

https://doi.org/10.1111/imr.12064
https://doi.org/10.4314/ejhd.v25i1.69853
https://doi.org/10.1038/s41577-018-0085-4
https://doi.org/10.1111/hiv.12424
https://doi.org/10.1038/s41541-021-00354-z
https://doi.org/10.1038/s41541-021-00354-z

